查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1722507

2025 年至 2033 年發作性睡病藥物市場報告（按類型、疾病類型、治療類型和地區分類）

Narcolepsy Drugs Market Report by Type, Disease Type, Therapeutic Type, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

2024 年全球嗜睡症藥物市場規模達 35 億美元。展望未來， IMARC Group預計到 2033 年市場規模將達到 65 億美元，2025-2033 年期間的成長率 (CAGR) 為 6.64%。人們對嗜睡症的認知和診斷不斷提高、睡眠障礙的盛行率不斷上升、藥物開發的不斷進步以及有利的監管環境是推動市場成長的主要因素。

嗜睡症藥物是指用於治療慢性睡眠障礙的藥物。這種疾病的特徵是白天過度嗜睡 (EDS)、猝倒或肌肉力量突然喪失、睡眠癱瘓、幻覺、睡眠片段化和失眠。其他症狀可能包括無意識的自動行為、視力模糊、複視或眼瞼下垂以及精神功能失調。患有嗜睡症的患者每天的睡眠時間與正常人相同；但睡眠品質往往較差。一些常用的治療嗜睡症的藥物包括中樞神經系統興奮劑、羥基丁酸鈉、選擇性血清素再攝取抑制劑和三環抗憂鬱劑。這些藥物有助於提高成年患者的覺醒程度，並減少幻覺、嗜睡和猝倒症。

嗜睡症藥物市場趨勢：

全球嗜睡症盛行率的不斷上升是推動市場成長的關鍵因素之一。這可以歸因於工作人群久坐的生活方式和忙碌的日程安排，這反過來又大大增加了睡眠相關疾病的發生率。此外，群眾健康意識的不斷增強以及對可用治療替代方案的認知不斷提高，為市場成長提供了動力。同時，羥基丁酸鈉在兒童嗜睡症治療的廣泛應用也促進了市場的成長。此外，嗜睡症診斷技術的顯著進步也起到了促進作用。製藥商也在開發具有長期效益和減少副作用的藥物。其他因素，包括老年人口的增加（老年人更容易患此類疾病）以及神經病學領域的廣泛研究和發展 (R&D) 活動，預計將推動市場成長。

本報告回答的關鍵問題

  • 嗜睡症藥物市場有多大？嗜睡症藥物市場的未來前景如何？
  • 推動嗜睡症藥物市場發展的關鍵因素有哪些？
  • 哪個地區佔據嗜睡症藥物最大的市佔率？
  • 全球嗜睡症藥物市場領先的公司有哪些？

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

  • 概述
  • 主要行業趨勢

第5章：全球嗜睡症藥物市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場細分：依類型

  • 伴隨猝倒症的嗜睡症
  • 無猝倒症的發作性睡病
  • 繼發性嗜睡症

第7章：市場區隔：依疾病類型

  • 白天極度嗜睡
  • 猝倒症
  • 其他

第8章：市場區隔：依治療類型

  • 羥基丁酸鈉
  • 中樞神經系統興奮劑
  • 三環抗憂鬱藥
  • 選擇性血清素再攝取抑制劑
  • 其他

第9章：市場細分：依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場區隔：依國家

第10章：SWOT分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第13章：價格分析

第 14 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Avadel Pharmaceuticals plc
    • Axsome Therapeutics Inc.
    • Bioprojet Pharma
    • Graymark Healthcare Inc.
    • Jazz Pharmaceuticals plc
    • Ligand Pharmaceuticals Incorporated
    • Novartis AG
    • SHIONOGI & Co. Ltd.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112025A5685

The global narcolepsy drugs market size reached USD 3.5 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 6.5 Billion by 2033, exhibiting a growth rate (CAGR) of 6.64% during 2025-2033. The increasing awareness and diagnosis of narcolepsy, growing prevalence of sleep disorders, ongoing advancements in drug development, and favorable regulatory environment are primarily driving the market's growth.

Narcolepsy drugs refer to pharmaceutical medicines used for the treatment of chronic sleep disorders. The disorder is characterized by excessive daytime sleepiness (EDS), cataplexy or sudden loss of muscle strength, sleep paralysis, hallucinations, fragmented sleep and insomnia. Additional symptoms may include automatic behaviors without conscious awareness, blurred vision, double vision or droopy eyelids and disturbed mental functioning. Patients suffering from narcolepsy tend to sleep the same number of hours per day as normal individuals; however, sleep quality tends to be poorer. Some of the commonly used narcolepsy drugs include central nervous system stimulants, sodium oxybate, selective serotonin reuptake inhibitors and tricyclic antidepressants. These drugs aid in improving wakefulness in adult patients and minimizing hallucinations, sleepiness and cataplexy.

Narcolepsy Drugs Market Trends:

The increasing prevalence of narcolepsy across the globe is one of the key factors driving the growth of the market. This can be attributed to the sedentary lifestyles and hectic schedules of the working population, which, in turn, is significantly increasing the incidences of sleep-related disorders. Moreover, rising health consciousness among the masses and the increasing awareness regarding the available treatment alternatives are providing a thrust to the market growth. In line with this, the widespread adoption of sodium oxybate for the treatment of narcolepsy in children is also contributing to the growth of the market. Additionally, significant improvements in the diagnostic technologies for narcolepsy are acting as other growth-inducing factors. Pharmaceutical manufacturers are also developing variants with long-term benefits and reduced side effects. Other factors, including the rising geriatric population, which is more susceptible to such ailments, along with extensive research and development (R&D) activities in the field of neurology, are anticipated to drive the market toward growth.

Key Market Segmentation:

Breakup by Type:

  • Narcolepsy with Cataplexy
  • Narcolepsy without Cataplexy
  • Secondary Narcolepsy

Breakup by Disease Type:

  • Daytime Extreme Sleepiness
  • Cataplexia
  • Others

Breakup by Therapeutic Type:

  • Sodium Oxybate
  • Central Nervous System Stimulants
  • Tricyclic Antidepressants
  • Selective Serotonin Reuptake Inhibitor
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Avadel Pharmaceuticals plc, Axsome Therapeutics Inc., Bioprojet Pharma, Graymark Healthcare Inc., Jazz Pharmaceuticals plc, Ligand Pharmaceuticals Incorporated, Novartis AG, SHIONOGI & Co. Ltd., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

  • 1.How big is the narcolepsy drugs market?
  • 2.What is the future outlook of narcolepsy drugs market?
  • 3.What are the key factors driving the narcolepsy drugs market?
  • 4.Which region accounts for the largest narcolepsy drugs market share?
  • 5.Which are the leading companies in the global narcolepsy drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Narcolepsy Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Narcolepsy with Cataplexy
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Narcolepsy without Cataplexy
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Secondary Narcolepsy
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Daytime Extreme Sleepiness
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cataplexia
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Therapeutic Type

  • 8.1 Sodium Oxybate
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Central Nervous System Stimulants
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Tricyclic Antidepressants
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Selective Serotonin Reuptake Inhibitor
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Avadel Pharmaceuticals plc
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Axsome Therapeutics Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
    • 14.3.3 Bioprojet Pharma
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Graymark Healthcare Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Jazz Pharmaceuticals plc
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Ligand Pharmaceuticals Incorporated
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Novartis AG
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 SHIONOGI & Co. Ltd.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Takeda Pharmaceutical Company Limited
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Teva Pharmaceutical Industries Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Narcolepsy Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Narcolepsy Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Narcolepsy Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Narcolepsy Drugs Market: Breakup by Type (in %), 2024
  • Figure 5: Global: Narcolepsy Drugs Market: Breakup by Disease Type (in %), 2024
  • Figure 6: Global: Narcolepsy Drugs Market: Breakup by Therapeutic Type (in %), 2024
  • Figure 7: Global: Narcolepsy Drugs Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Narcolepsy Drugs (Narcolepsy with Cataplexy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Narcolepsy Drugs (Narcolepsy with Cataplexy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Narcolepsy Drugs (Narcolepsy without Cataplexy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Narcolepsy Drugs (Narcolepsy without Cataplexy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Narcolepsy Drugs (Secondary Narcolepsy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Narcolepsy Drugs (Secondary Narcolepsy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Narcolepsy Drugs (Daytime Extreme Sleepiness) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Narcolepsy Drugs (Daytime Extreme Sleepiness) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Narcolepsy Drugs (Cataplexia) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Narcolepsy Drugs (Cataplexia) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Narcolepsy Drugs (Other Disease Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Narcolepsy Drugs (Other Disease Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Narcolepsy Drugs (Sodium Oxybate) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Narcolepsy Drugs (Sodium Oxybate) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Narcolepsy Drugs (Central Nervous System Stimulants) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Narcolepsy Drugs (Central Nervous System Stimulants) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Narcolepsy Drugs (Tricyclic Antidepressants) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Narcolepsy Drugs (Tricyclic Antidepressants) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Narcolepsy Drugs (Selective Serotonin Reuptake Inhibitor) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Narcolepsy Drugs (Selective Serotonin Reuptake Inhibitor) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Narcolepsy Drugs (Other Therapeutic Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Narcolepsy Drugs (Other Therapeutic Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: North America: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: North America: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: United States: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: United States: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Canada: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Canada: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Asia-Pacific: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Asia-Pacific: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: China: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: China: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Japan: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Japan: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: India: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: India: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: South Korea: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: South Korea: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Australia: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Australia: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Indonesia: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Indonesia: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Others: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Others: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Europe: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Europe: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Germany: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Germany: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: France: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: France: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: United Kingdom: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: United Kingdom: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Italy: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Italy: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Spain: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Spain: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Russia: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Russia: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Others: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Others: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Latin America: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Latin America: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Brazil: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Brazil: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Mexico: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Mexico: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Others: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Others: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Middle East and Africa: Narcolepsy Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Middle East and Africa: Narcolepsy Drugs Market: Breakup by Country (in %), 2024
  • Figure 78: Middle East and Africa: Narcolepsy Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Global: Narcolepsy Drugs Industry: SWOT Analysis
  • Figure 80: Global: Narcolepsy Drugs Industry: Value Chain Analysis
  • Figure 81: Global: Narcolepsy Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Narcolepsy Drugs Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Narcolepsy Drugs Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 3: Global: Narcolepsy Drugs Market Forecast: Breakup by Disease Type (in Million USD), 2025-2033
  • Table 4: Global: Narcolepsy Drugs Market Forecast: Breakup by Therapeutic Type (in Million USD), 2025-2033
  • Table 5: Global: Narcolepsy Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Narcolepsy Drugs Market: Competitive Structure
  • Table 7: Global: Narcolepsy Drugs Market: Key Players